Regulus Therapeutics, the microRNA drug joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, has filed with US regulators to begin selling its shares on the public market.
NEW YORK (GenomeWeb News) – Atossa Genetics lowered the expected share price for its planned initial public offering to between $4 and $6 per share, it disclosed in an amended Form S-1 filed on Monday with the US Securities and Exchange Commission.
NEW YORK (GenomeWeb News) – Venture capital investing into the 'omics-related and molecular diagnostics space remains challenging and is unlikely to improve in the near-term, according to some VC fund managers.
NEW YORK (GenomeWeb News) – Atossa Genetics, which refiled for an initial public offering earlier this year, said in its amended Form S-1 that it net loss for full-year 2011 reached $3.4 million.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Almost one year to the day after pulling a planned initial public offering, Seattle-based Atossa Genetics has refiled with US regulators to go public.
